Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vulvar Cancer - Overview
Vulvar Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vulvar Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vulvar Cancer - Companies Involved in Therapeutics Development
Antiva Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Brooklyn ImmunoTherapeutics LLC
Cutanea Life Sciences Inc
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Invectys SA
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Ono Pharmaceutical Co Ltd
Shanghai Bovax Biotechnology Co Ltd
SQZ Biotechnologies Co
Transgene SA
Turnstone Biologics Inc
Vulvar Cancer - Drug Profiles
Vulvar Cancer - Dormant Projects
Vulvar Cancer - Discontinued Products
Vulvar Cancer - Product Development Milestones
Appendix



List of Figures


Number of Products under Development for Vulvar Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Vulvar Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Vulvar Cancer - Pipeline by Antiva Biosciences Inc, H2 2019
Vulvar Cancer - Pipeline by AstraZeneca Plc, H2 2019
Vulvar Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
Vulvar Cancer - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2019
Vulvar Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Vulvar Cancer - Pipeline by Gilead Sciences Inc, H2 2019
Vulvar Cancer - Pipeline by Invectys SA, H2 2019
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2019
Vulvar Cancer - Pipeline by Merck & Co Inc, H2 2019
Vulvar Cancer - Pipeline by Merck KGaA, H2 2019
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Vulvar Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019
Vulvar Cancer - Pipeline by SQZ Biotechnologies Co, H2 2019
Vulvar Cancer - Pipeline by Transgene SA, H2 2019
Vulvar Cancer - Pipeline by Turnstone Biologics Inc, H2 2019
Vulvar Cancer - Dormant Projects, H2 2019